Four core areas of medical-affairs activity combine to maximize patient experiences and outcomes.
Medical-device players are venturing into adjacent value pools through solutions and services. What do they require to capitalize on the opportunity and deliver on their profitable growth aspirations?
Biopharma in China is poised for change that will transform commercial and operating models, and require a step change in capabilities.
Established companies with long histories of performance, increasingly face new competitors with no track record and lower prices. What’s the value of experience?
Vaccine development has slowed over the past five years, but changes to investment strategies and a shift in focus to more technical and complex vaccines could renew the innovation engine.
Affordable biologic therapies could help expand patients’ access to treatment in the developing world. Here’s what pharma companies must know to unlock the potential.
For medtech companies, divestitures can create value. But several elements are necessary to make separations successful.
The Head of Digital Strategy and Medical Innovation, US Clinical Development and Medical Affairs at Novartis discusses how disruptive technologies and digital innovation are inspiring a start-up mind-set within the organization.